# EDGAR Filing Document

**Accession Number:** 0001191070
**File Stem:** 0000950170-23-003904
**Filing Date:** 2023-2
**Character Count:** 12672
**Document Hash:** 3b31f1f644bbde606bfb7f9d11d5a8c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-003904.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0000950170-23-003904

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230223

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIONOMICS LIMITED/FI
- **CENTRAL INDEX KEY:** 0001191070
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** C3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41157
- **FILM NUMBER:** 23655789

**BUSINESS ADDRESS:**
- **STREET 1:** 200 GREENHILL ROAD
- **CITY:** EASTWOOD SA
- **STATE:** C3
- **ZIP:** 5063
- **BUSINESS PHONE:** 61 8 8150 7400

**MAIL ADDRESS:**
- **STREET 1:** 200 GREENHILL ROAD
- **CITY:** EASTWOOD SA
- **STATE:** C3
- **ZIP:** 5063

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K** 

------

**REPORT OF FOREIGN ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of February, 2023** 

**(Commission File No. 001-41157)** 

------

**BIONOMICS LIMITED**

**(Translation of registrant's name into English)** 

------

**200 Greenhill Road**

**Eastwood SA 5063**

**Tel: +618 8150 7400**

**(Address of registrant's principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☐

------

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On February 23, 2023, the Company lodged a Change in Director's Interest Notice on behalf of directors Dr Errol De Souza and Dr Spyros Papapetropoulos on Appendix 3Y with the ASX, as required by the laws and regulations of Australia, to disclose a change in interests in securities and contracts of the Company. The Change in Director's Interest Notices for Dr Errol De Souza and Dr Spyros Papapetropoulos are furnished herewith as Exhibit 99.1 and 99.2 respectively to this report on Form 6-K.

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit**<br>| &nbsp;&nbsp;&nbsp;**Description**<br>|
| &nbsp;&nbsp;99.1 | [<u>Appendix 3Y_Change of Directors Interest Notice_EDS</u>](bnox-ex99_1.htm) |
| &nbsp;&nbsp;99.2 | [<u>Appendix 3Y_Change of Directors Interest Notice_SP</u>](bnox-ex99_2.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | |
|:---|:---|
| **Bionomics Limited** | **Bionomics Limited** |
| (Registrant) | (Registrant) |
| By: | /s/ Errol De Souza<br>|
| Name: | Errol De Souza, Ph.D. |
| Title: | Chairman of the Board |

---

Date: February 23, 2023

------

## Ex-99

**Exhibit 99.1**

**Appendix 3Y**

**Change of Director's Interest Notice**

------

Rule 3.19A.2

**Appendix 3Y**

**Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

---

| |
|:---|
| **Name of entity Bionomics Limited** |
| **ABN 53 075 582 740** |

---

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Name of Director** | &nbsp;&nbsp;Dr Errol De Souza |
| &nbsp;&nbsp;**Date of last notice** | &nbsp;&nbsp;28 November 2022 |

---

**Part 1 - Change of director's relevant interests in securities**

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Direct or indirect interest** | &nbsp;&nbsp;Direct |
| &nbsp;&nbsp;**Nature of indirect interest**<br>**(including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest.<br>|  |
| &nbsp;&nbsp;**Date of change** | &nbsp;&nbsp;23 February 2023 |
| &nbsp;&nbsp;**No. of securities held prior to change** | &nbsp;&nbsp;366,698 Fully Paid Ordinary Shares<br>400,000 Unlisted Options issued in Nov 2016<br>12,000,000 Unlisted Options issued in Aug 2020<br>61,216,767 Unlisted Options issued in Dec 2021 |
| &nbsp;&nbsp;**Class** | &nbsp;&nbsp;Unlisted Options |
| &nbsp;&nbsp;**Number acquired** | &nbsp;&nbsp;10,000,000 Unlisted Options |
| &nbsp;&nbsp;**Number disposed** | &nbsp;&nbsp;1,666,667 Unlisted Options |
| &nbsp;&nbsp;**Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation<br>| &nbsp;&nbsp;Nil |
| &nbsp;&nbsp;**No. of securities held after change** | &nbsp;&nbsp;366,698 Fully Paid Ordinary Shares<br>400,000 Unlisted Options issued in Nov 2016<br>12,000,000 Unlisted Options issued in Aug 2020<br>61,216,767 Unlisted Options issued in Dec 2021<br>8,333,333 Unlisted Options issued in Feb 2023 |

---

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

------

**Appendix 3Y**

**Change of Director's Interest Notice**

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | &nbsp;&nbsp;Grant of unlisted Options as part of Dr Errol 's remuneration as Executive Chair to 31 December 2022 which was approved by shareholders at a general meeting held on 21 February 2023.<br>Lapsing of 1,666,667 Unlisted Options which failed to meet vesting conditions related to the successful data readout for Phase 2 trial for BNC210 in SAD as reasonably determined by the Board in its sole discretion. |

---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Detail of contract** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Nature of interest**<br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Name of registered holder**<br>**(if issued securities)**<br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Date of change** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed<br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Interest acquired** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Interest disposed** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation <br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Interest after change** | &nbsp;&nbsp;N/A |

---

**Part 3 –** +**Closed period**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Were the interests in the securities or contracts detailed above traded during a** +**closed period where prior written clearance was required?** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**If so, was prior written clearance provided to allow the trade to proceed during this period?** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**If prior written clearance was provided, on what date was this provided?** | &nbsp;&nbsp;N/A |

---

+ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

------

**Appendix 3Y**

**Change of Director's Interest Notice**

------

+ See chapter 19 for defined terms.

Appendix 3Y Page 3 01/01/2011

------

## Ex-99

**Exhibit 99.2**

**Appendix 3Y**

**Change of Director's Interest Notice**

------

Rule 3.19A.2

**Appendix 3Y**

**Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

---

| |
|:---|
| **Name of entity Bionomics Limited** |
| **ABN 53 075 582 740** |

---

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Name of Director** | &nbsp;&nbsp;Spyridon Papapetropoulos |
| &nbsp;&nbsp;**Date of last notice** | &nbsp;&nbsp;9 January 2023 |

---

**Part 1 - Change of director's relevant interests in securities**

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Direct or indirect interest** | &nbsp;&nbsp;Direct |
| &nbsp;&nbsp;**Nature of indirect interest**<br>**(including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest.<br>|  |
| &nbsp;&nbsp;**Date of change** | &nbsp;&nbsp;23 February 2023 |
| &nbsp;&nbsp;**No. of securities held prior to change** | &nbsp;&nbsp;Nil |
| &nbsp;&nbsp;**Class** | &nbsp;&nbsp;Unlisted Options |
| &nbsp;&nbsp;**Number acquired** | &nbsp;&nbsp;27,067,015 Unlisted Options |
| &nbsp;&nbsp;**Number disposed** | &nbsp;&nbsp;Nil |
| &nbsp;&nbsp;**Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation<br>| &nbsp;&nbsp;Nil |
| &nbsp;&nbsp;**No. of securities held after change** | &nbsp;&nbsp;27,067,015 Unlisted Options issued in Feb 2023 |
| &nbsp;&nbsp;**Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | &nbsp;&nbsp;Grant of unlisted Options which was approved by shareholders at the general meeting held on 21 February 2023.<br>|

---

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

------

**Appendix 3Y**

**Change of Director's Interest Notice**

------

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Detail of contract** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Nature of interest**<br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Name of registered holder**<br>**(if issued securities)**<br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Date of change** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed<br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Interest acquired** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Interest disposed** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation <br>| &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**Interest after change** | &nbsp;&nbsp;N/A |

---

**Part 3 –** +**Closed period**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Were the interests in the securities or contracts detailed above traded during a** +**closed period where prior written clearance was required?** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**If so, was prior written clearance provided to allow the trade to proceed during this period?** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**If prior written clearance was provided, on what date was this provided?** | &nbsp;&nbsp;N/A |

---

+ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

------